The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study
Elena Campione,Sara Mazzilli,Caterina Lanna,Terenzio Cosio,Vincenzo Palumbo,Gaia Cesaroni,Flavia Lozzi,Laura Diluvio,Luca Bianchi
DOI: https://doi.org/10.2147/CCID.S231313
2019-12-16
Abstract:Elena Campione, Sara Mazzilli, Caterina Lanna, Terenzio Cosio, Vincenzo Palumbo, Gaia Cesaroni, Flavia Lozzi, Laura Diluvio, Luca Bianchi Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy Correspondence: Elena Campione Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 81, Rome 00133, Italy Tel +39 0620902743 Email campioneelena@hotmail.com Introduction: Seborrheic dermatitis is a common skin disease with clinical aspects similar to those of psoriasis, eczema or allergic reactions, appearing on the sebum-rich areas of the scalp, face, and trunk. Yeast like Malassezia species, immunologic abnormalities and activation of complement are recognized as a crucial pathogen for the onset of seborrheic dermatitis. Intermittent and active phases are characterized by burning, scaling and itching, then followed by inactive periods. The disease is sometimes severe up to the erythrodermia; thus, it has a great influence on the patient's quality of life. In vitro and vivo studies have shown that the exogenous intake of glutathione-GSH-C4 and tocopherol inhibits lipid peroxidation and effectively fights and reduces oxidative stress in inflammatory disorders. Methods: We have carried out a study enrolling 20 patients affected by SD to evaluate the effectiveness and tolerability of a new topical formulation in cream (hereinafter SEB) containing GSH-C4 0.4% in hyaluronic acid 0.25% – a new synthetic glutathione derivate called INCI (butyroyl glutathione)-assigned by the Personal Care Council. Investigator Global Assessment score and Patient Global Assessment of Treatment scales were used to test the efficacy of this new formulation. Results: All patients showed a good clinical response to the treatment with topical SEB demonstrated by the gradual reduction in inflammatory skin lesions. Discussion: The results of our pilot study confirm the efficacy and tolerability of this new topical formulation in a real-life assessment and patients showed strong adherence to therapy. These promising results – still to be confirmed on a larger number of patients – emphasize the potential SEB has in controlling the chronic inflammation of seborrheic dermatitis. Keywords: seborrheic dermatitis, glutathione, pilot study
dermatology